Functional commitment of monocyte derived dendritic cells from cancer patients: involvement of p38 and ERK1/2 (p44/p42) MAPK signaling pathways.

Author(s)

Bruna Zelante Barbosa

• Document type: Doctoral Thesis
• Press: São Paulo.
• Institution: Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB/SDI)
• Defense date: 2017-02-09

Examining board members

Jose Alexandre Marzagao Barbuto; José Antonio Tavares de Albuquerque; Sonia Jancar Negro; Elaine Guadelupe Rodrigues; Telma Miyuki Oshiro Sumida

• Advisor: Jose Alexandre Marzagao Barbuto

Abstract

Dendritic cells are the main presenting cells and present alterations in cancer patients. The signaling pathways p38 and ERK1/2 MAPK participate of monocyte-derived dendritic cells (Mo-DCs) differentiation. Exposition to MCF-7s supernatant (TS) decreased CD14 and CD1a expression (frequency) while enhanced IL-6 and IL-10 production. Inhibition of ERK1/2 MAPK reverted CD14 expression and partially reverted cytokines production. Inhibition of p38 MAPK reverted CD1a and CD14 expression and partially reverted cytokines production too. We identified the heat shock protein HSP27. Exposition to HSP27 did not cause the observed alterations seen when the cells were exposed to TS. Lastly, treatment of Mo-DCs from breast cancer patients with the p38 inhibitor decreased CD86 and HLA-DR expression. Therefore, the data presented in this study suggest that p38 MAPK inhibition does not appear to be an interesting approach in the manipulation of Mo-DCs from breast cancer patients. (AU)

• FAPESP's process: 12/13428-6 - Functional impairment of monocyte-derived dendritic cells in cancer patients: involvement of p38 and ERK (p44/p42) MAPK signaling pathway
• Grantee: Bruna Zelante Barbosa
• Support Opportunities: Scholarships in Brazil - Doctorate (Direct)